GleamWall
中文EN

NAMS NewAmsterdam Pharma Co N.V.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1936258 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-26.4%
TTM net income YoY7.3%
TTM EPS YoY17.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-900.1%
Net margin-789.9%
FCF margin-581.6%
EBITDA margin-899.0%

Returns

ROE-30.2%
ROA-27.8%
ROIC (approx.)-92.8%
Asset turnover0.04x

Leverage & solvency

Liabilities / assets8.3%
Debt / equity0.00x
Current ratio11.76x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue1.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$19.16M$3.70M$3.04M$32,000$348,000$19.14M$2.98M$12.77M
R&D expense$39.36M$41.67M$38.01M$38.59M$30.97M$27.52M$44.75M$34.90M
SG&A expense$24.00M$26.89M$23.45M$27.42M$24.52M$27.26M$27.15M$21.11M
Operating income-$44.19M-$64.86M-$58.42M-$65.98M-$55.14M-$35.63M-$68.92M-$43.23M
Pretax income-$16.18M-$64.14M-$48.44M-$74.92M-$72.00M-$17.36M-$39.53M-$92.18M
Income tax$1.21M——————$0
Net income-$17.39M-$64.14M-$48.44M-$74.92M-$72.00M-$17.36M-$39.53M-$92.18M
EBITDA-$44.12M-$64.78M-$58.36M-$65.92M-$55.02M-$35.53M-$68.87M-$43.18M
EPS (basic)-0.14-0.52-0.40—-0.61-0.15-0.34—
EPS (diluted)-0.14-0.52-0.40—-0.61-0.15-0.34—
Weighted avg. shares (diluted)124.14M123.37M121.72M—119.00M118.56M116.12M—
Balance sheet
Cash & equivalents$423.13M$424.15M$457.61M$490.00M$538.41M$563.86M$748.42M$771.74M
Short-term investments$205.11M$209.70M$178.50M$146.24M$164.54M$175.30M$60.06M$62.45M
Current assets$672.16M$659.21M$658.04M$675.70M$732.33M$769.85M$817.30M$863.41M
PP&E, net$554,000$411,000$379,000$383,000$323,000$312,000$238,000$242,000
Total assets$687.99M$704.45M$732.64M$769.28M$786.43M$815.11M$818.41M$864.62M
Current liabilities$57.15M$72.97M$67.42M$85.79M$58.27M$36.51M$40.91M$106.92M
Total liabilities$57.20M$73.03M$67.42M$85.85M$58.36M$36.62M$41.05M$107.12M
Shareholders' equity$630.78M$631.42M$665.22M$683.43M$728.07M$778.50M$777.36M$757.50M
Shares outstanding119.82M117.65M116.64M114.40M113.17M112.51M112.17M108.06M
Cash flow statement
Operating cash flow-$39.77M-$39.21M-$30.60M-$40.88M-$32.77M-$37.67M-$36.47M-$37.48M
Capital expenditure$177,000$80,000$38,000$100,000$42,000$88,000$16,000$3,000
Free cash flow-$39.95M-$39.29M-$30.64M-$40.98M-$32.81M-$37.76M-$36.48M-$37.48M
Investing cash flow$33.70M-$4.76M-$11.51M-$21.14M$2.51M-$159.14M$2.85M-$62.18M
Financing cash flow$5.45M$11.04M$11.06M$13.68M$5.89M$3.42M$6.52M$456.61M
Depreciation & amortization$67,000$89,000$62,000$59,000$125,000$107,000$52,000$51,000
Stock-based compensation$12.52M$18.38M$18.00M$14.02M$15.01M$15.18M$15.21M$9.41M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.